My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 2 111 / https://doi.org/10.3332/ecancer.2008.111

Case Report

Pegylated Liposomal Doxorubicin (PLD): enhanced skin toxicity in areas of vitiligo

Pegylated liposomal doxorubicin (PLD, Doxil, Caelyx) is widely used for the treatment of ovarian cancer. It is a stable formulation encapsulating doxorubicin in a ‘Stealth’ (i.e., pegylated) liposome with a half-life of about 72 hours. This drastically altered pharmacology confers on it a considerably lower risk of cardiotoxicity, no acute emesis, and near absence of alopecia or problems with extravasation necrosis. On the other hand, PLD's dose-limiting toxicity is cutaneous. Since the original phase I report, cutaneous toxicities reported with PLD fall into four common categories: the well known hand-foot syndrome (also called palmoplantar erythrodysesthesia, or PPE), a diffuse follicular rash, intertrigo-like eruption, and hyperpigmentation including melanotic macules.

Loading Article Metrics ... Please wait

Related articles

Short Communication: Cancer treatment in the last 6 months of life: when inaction can outperform action

Abstract | Full Article | PDF Published: 18 Apr 2018 / https://doi.org/10.3332/ecancer.2018.826

Conference Report: Highlights from the 10th Breast, Gynaecological and Immunotherapy International Cancer Conference (BGICC), 18–19 January 2018, Cairo, Egypt

Abstract | Full Article | PDF Published: 22 Mar 2018 / https://doi.org/10.3332/ecancer.2018.820

Research: Cosmesis after early stage breast cancer treatment with surgery and radiation therapy: experience of patients treated in a Chilean radiotherapy centre

Abstract | Full Article | PDF Published: 21 Mar 2018 / https://doi.org/10.3332/ecancer.2018.819

Case Report: Cauda equina syndrome secondary to leptomeningeal metastases from recurrent primary peritoneal carcinoma

Abstract | Full Article | PDF Published: 26 Feb 2018 / https://doi.org/10.3332/ecancer.2018.814

Case Report: Palliative hysterectomy for vaginal bleeding from breast cancer metastatic to the uterus

Abstract | Full Article | PDF Published: 14 Feb 2018 / https://doi.org/10.3332/ecancer.2018.811



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence